The FDA keeps offering up tough news to Johnson & Johnson for its warfarin replacement, Xarelto. It has twice turned it down for treatment of acute coronary syndrome (ACS), and today the company said it had a complete response letter for use of the bloodthinner to prevent stent thrombosis in patients with ACS.
Two developers of biosimilars won a major victory in Europe. A European Union regulator backed approval of two copycat versions of Johnson & Johnson's blockbuster therapy Remicade, meaning the healthcare giant could face competition from new low-cost rivals in the European market.
The Cambridge, MA, center is one of four planned by J&J.
Johnson & Johnson has invested in a pair of biotech upstarts in the Boston area as the healthcare giant seeks more deals and partnerships with external innovators. Also, J&J's previously disclosed Boston Innovation Center officially opened in Cambridge, MA, to serve as a regional hub for collaborations on early-stage science and technology.
Doctors who prescribe certain brands the most also have financial ties to the companies that make them, a ProPublica investigation found. Coincidence? Experts think not.
Johnson & Johnson's Animas division revealed results Friday from the second phase of clinical trials for its artificial pancreas candidate, demonstrating that the device maintained safe glucose levels overnight.
J&J expects its McNeil Consumer Healthcare division to be set free of a two-year-old FDA consent decree by year's end. That order has kept its main OTC plant in Fort Washington, PA, closed and placed strict oversight on two others.
Johnson & Johnson says that by year's end it can start ticking off the punch list with the FDA at its Fort Washington, PA, manufacturing site, setting the stage for shedding a federal consent decree.
The Arkansas Supreme Court is the epicenter of the latest episode in Johnson & Johnson's Risperdal saga. J&J is appealing the $1.2 billion fine in a Medicaid fraud case, in which a jury found the company had downplayed Risperdal's risks and marketed it for off-label uses.
A Delaware jury ruled that Globus Medical violated three patents owned by Johnson & Johnson, ordering the company to fork over $16 million in damages.